The short answer
Proglucagon is a single precursor protein cut into different products in different tissues. The usual account credits one enzyme in the gut and another in the pancreas, but reconstitution experiments show the second enzyme does not produce glucagon on its own.
Key facts
- Precursor
- Proglucagon, one gene product
- Intestinal products
- Glicentin, oxyntomodulin, GLP-1, GLP-2
- Pancreatic product
- Glucagon
- Enzyme credited in gut
- PC1, also written PC1/3
- Enzyme credited in pancreas
- PC2
- What PC1 produced in vitro
- Glicentin, oxyntomodulin, GLP-1(1-37), GLP-1(7-37), GLP-2
- What PC2 produced in vitro
- Glicentin only, no glucagon
- GLP-2 length
- 33 amino acids
The economy of one gene
Glucagon raises blood glucose. GLP-1 lowers it and suppresses appetite. GLP-2 grows intestinal mucosa. Oxyntomodulin does several of these things weakly at once. They are not related hormones that evolved in parallel. They are pieces of a single precursor protein, cut apart differently depending on which cell does the cutting. That is unusual even by the standards of prohormone biology, because the products are hormones with opposing metabolic effects rather than variations on a theme, and the same gene is transcribed in the pancreatic alpha cell, the intestinal L cell and parts of the brain.
The standard account
The version in most textbooks and reviews is simple. Prohormone convertases are the enzymes that cut precursors at basic residue pairs. The intestinal L cell expresses PC1 (also written PC1/3), and cutting proglucagon with PC1 liberates the intestinal set: glicentin, oxyntomodulin, GLP-1 and GLP-2. The pancreatic alpha cell expresses PC2, and cutting with PC2 liberates glucagon along with the major proglucagon fragment. Which peptides a cell makes therefore follows from which convertase it expresses. It is a neat explanation, and it needs checking.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What the reconstitution experiments actually found
Dhanvantari, Seidah and Brubaker tested it directly in 1996 by expressing proglucagon in cells and supplying convertases one at a time. PC1 behaved as advertised: in endocrine GH3 and AtT-20 cells it produced glicentin, oxyntomodulin, GLP-1(1-37), GLP-1(7-37) and GLP-2. PC2 did not. In one system it failed to process proglucagon at all; elsewhere it produced glicentin and stopped there. The authors state the negative result clearly: no enzyme or combination they tested produced glucagon. Adding furin, PACE4, PC5a or PC5b did not help. Nor did co-expressing PC2 with chromogranin A, chromogranin B, secretogranin II, or 7B2, the chaperone PC2 requires to mature. Supplying the enzyme credited with making glucagon, in the presence of its own chaperone, did not make glucagon.
And the same result in a real cell
That could have been an artefact of reconstituting the system in cells that do not normally do this. Damholt and colleagues tested it in primary canine intestinal L cells, which do express proglucagon endogenously. They confirmed by immunohistochemistry and Western blot that PC1/3, PC2 and mature 7B2 were all present in those cells. The peptides produced were the classical intestinal profile (mainly glicentin, oxyntomodulin, GLP-1(7-37) and GLP-2), and they detected, in their phrase, absolute minimal amounts of glucagon. A cell containing proglucagon, PC2 and 7B2 together still did not make glucagon.
What that leaves unexplained, and why it matters
The authors' conclusion is that glucagon formation must require an additional element, or that the components are held in separate intracellular compartments so that the enzyme and the substrate never meet. Either way, the determinant of tissue-specific processing is not simply which convertase is present, because the presence of PC2 is demonstrably not sufficient. Something about the alpha cell beyond its enzyme complement, whether additional factors or the physical organisation of its secretory pathway, decides the outcome. The clean version of the story survives as a useful summary but not as a mechanism, and the papers that showed this are thirty and twenty-seven years old.
Why a peptide reference library cares
Because this is where the modern compound landscape comes from. Dual and triple agonists are built by combining activities that proglucagon already contains: GLP-1 with glucagon, GLP-1 with GIP and glucagon, oxyntomodulin as a naturally occurring dual agonist. Reviews of proglucagon-derived peptides as therapeutics describe this approach, designing analogues around a set of related activities that a single precursor encodes. Understanding that these are fragments of one protein explains why their receptor selectivities overlap and why a molecule can be tuned along a spectrum between them rather than being either one thing or the other.
Quick reference
| Peptide | Principal source | Main described action |
|---|---|---|
| Glucagon | Pancreatic alpha cell | Raises blood glucose |
| GLP-1 | Intestinal L cell | Glucose-dependent insulin release, appetite |
| GLP-2 | Intestinal L cell | Intestinal mucosal growth |
| Oxyntomodulin | Intestinal L cell | Weak dual GLP-1 and glucagon receptor activity |
| Glicentin | Intestinal L cell | Poorly characterised |
Frequently asked questions
Does this mean PC2 has nothing to do with glucagon?
No. PC2 is required for glucagon production in the alpha cell, and animals lacking it have profoundly disturbed alpha-cell peptide processing. The finding is narrower and more interesting: PC2 is necessary but not sufficient, and supplying it to a proglucagon-containing cell does not by itself produce glucagon.
Why does GLP-1 exist as both 1-37 and 7-37?
The initial cleavage releases a longer form which is then trimmed to the biologically active one. Only the truncated forms activate the receptor usefully, which is why an assay that measures total GLP-1 and one that measures active GLP-1 can give very different answers about the same sample.
Is oxyntomodulin a separate hormone or a by-product?
It is a real secreted peptide with its own described activity at both the GLP-1 and glucagon receptors, weakly at each. That combination is what modern dual agonists are engineered to reproduce with greater potency, which is why it is treated as a template rather than a curiosity.
Where does GIP fit in?
It does not. GIP comes from a different gene and a different cell type, and is grouped with GLP-1 only because both are incretins. Assuming the incretins share a precursor is a common error.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedDhanvantari S et al., Role of prohormone convertases in the tissue-specific processing of proglucagon - Mol Endocrinol 1996 (PMID 8721980)pubmed.ncbi.nlm.nih.gov
- PubMedDamholt AB et al., Proglucagon processing profile in canine L cells expressing endogenous prohormone convertase 1/3 and prohormone convertase 2 - Endocrinology 1999 (PMID 10499540)pubmed.ncbi.nlm.nih.gov
- PubMedLafferty RA et al., Proglucagon-Derived Peptides as Therapeutics - Front Endocrinol 2021 (PMID 34093449)pubmed.ncbi.nlm.nih.gov
- PubMedDrucker DJ, The Discovery of GLP-2 and Development of Teduglutide for Short Bowel Syndrome - ACS Pharmacol Transl Sci 2019 (PMID 32219218)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- The Other Peptide the L Cell ReleasesGLP-2 is co-secreted with GLP-1 from the very same cells and does something entirely different. Its analogue teduglutide is a licensed prescription medicine.
- A Risk Ratio of 0.57 That Means Almost NothingOne meta-analysis reported RR 0.568 for suicidality with GLP-1 drugs. Its interval ran from 0.077 to 4.205, which is compatible with almost any answer.
- Adding a Warning Needs Suspicion; Removing One Needs EvidenceRegulators added a suicidality warning to GLP-1 labels on suspicion alone. Removing it again took two and a half years and a review of 91 randomised trials.
- The Receptors That Decide When GLP-1 Comes OutGlucose, fat and fermentation products are each detected by a different sensor on the same cell, and none of them works quite the way most explanations assume.
- The Nerve That Reads GLP-1 Before the Blood DoesKnocking down GLP-1 receptors on vagal afferents changed meal size and gastric emptying but not long-term body weight. That distinction matters enormously.